EPZM Epizyme Inc

Price (delayed)

$6.96

Market cap

$709.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.47

Enterprise value

$870.84M

Highlights
The company's revenue rose by 40% QoQ and by 28% YoY
The gross profit has grown by 38% from the previous quarter but it has contracted by 12% YoY
The equity has plunged by 64% YoY and by 33% from the previous quarter
The quick ratio has contracted by 43% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of EPZM
Market
Shares outstanding
101.98M
Market cap
$709.75M
Enterprise value
$870.84M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.76
Price to sales (P/S)
32.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.51
Earnings
Revenue
$22.04M
EBIT
-$240M
EBITDA
-$235.25M
Free cash flow
-$249.58M
Per share
EPS
-$2.47
Free cash flow per share
-$2.45
Book value per share
$1.21
Revenue per share
$0.22
TBVPS
$3.54
Balance sheet
Total assets
$406.71M
Total liabilities
$283.68M
Debt
$234.8M
Equity
$123.03M
Working capital
$301.41M
Liquidity
Debt to equity
1.91
Current ratio
8.73
Quick ratio
7.91
Net debt/EBITDA
-0.68
Margins
EBITDA margin
-1,067.4%
Gross margin
66.8%
Net margin
-1,139%
Operating margin
-1,081.7%
Efficiency
Return on assets
-59.4%
Return on equity
-118.7%
Return on invested capital
-62%
Return on capital employed
-65.3%
Return on sales
-1,089%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EPZM stock price

How has the Epizyme stock price performed over time
Intraday
-1.69%
1 week
-4%
1 month
-23.01%
1 year
-50.92%
YTD
-35.91%
QTD
-16.25%

Financial performance

How have Epizyme's revenue and profit performed over time
Revenue
$22.04M
Gross profit
$14.73M
Operating income
-$238.4M
Net income
-$251.03M
Gross margin
66.8%
Net margin
-1,139%
The company's revenue rose by 40% QoQ and by 28% YoY
The gross profit has grown by 38% from the previous quarter but it has contracted by 12% YoY
The gross margin has contracted by 31% YoY
The net income has contracted by 31% YoY and by 8% from the previous quarter

Growth

What is Epizyme's growth rate over time

Valuation

What is Epizyme stock price valuation
P/E
N/A
P/B
5.76
P/S
32.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.51
The EPS has decreased by 21% YoY and by 8% from the previous quarter
The equity has plunged by 64% YoY and by 33% from the previous quarter
The stock's P/B is 28% above its 5-year quarterly average of 4.5 but 2.4% below its last 4 quarters average of 5.9
EPZM's P/S is 61% below its last 4 quarters average of 82.7 and 58% below its 5-year quarterly average of 75.7
The company's revenue rose by 40% QoQ and by 28% YoY

Efficiency

How efficient is Epizyme business performance
Epizyme's ROE has plunged by 99% YoY and by 36% from the previous quarter
The ROS has increased by 24% from the previous quarter and by 5% YoY
The ROA has contracted by 22% YoY and by 11% from the previous quarter
EPZM's ROIC is up by 13% year-on-year and by 7% since the previous quarter

Dividends

What is EPZM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EPZM.

Financial health

How did Epizyme financials performed over time
The total assets is 43% more than the total liabilities
Epizyme's total liabilities has surged by 155% YoY
The quick ratio has contracted by 43% YoY and by 9% from the previous quarter
EPZM's debt is 91% more than its equity
The equity has plunged by 64% YoY and by 33% from the previous quarter
EPZM's debt to equity is up by 49% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.